Ovarian Cancer Patient Tool
Treatment Options From 5 Experts for Advanced Ovarian Cancer: An Online Tool for Patients

Released: May 21, 2020

Expiration: May 20, 2021

About This Tool & Disclaimer

Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer

Clinical Care Options, LLC, is grateful to Robert L. Coleman, MD; Thomas J. Herzog, MD; Ursula Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; and Kathleen Moore, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool reflects expert recommendations from September 2019.

The goal of the tool is to educate patients on possible treatment options for stage II-IV epithelial ovarian cancer in the frontline and second-line settings.

A series of questions allow the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include the intended treatment setting (newly diagnosed or recurrent disease), tumor subtype, the mutational status of your cancer, response to any previous systemic treatment (if appropriate), and whether the patient is eligible for certain types of therapy. It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with advanced-stage epithelial ovarian cancer. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes that the patient is an adult diagnosed with stage II-IV epithelial ovarian cancer for whom systemic therapy is indicated.

Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

This program is supported by independent educational grants from Clovis Oncology and Tesaro.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Robert L. Coleman, MD, has disclosed has disclosed that he has received consulting fees from AbbVie, Aravive, ArQule, AstraZeneca, Cell Medica, Clovis, Cordgenics, Eisai, Geistlich, Genentech, Genmab, ImmunoGen, Janssen, Merck, Mersana , Novocure, OncoMed,Takeda, and Tesaro; fees for non-CME/CE services from Merck and Roche; and funds for research support from AstraZeneca, Clovis, Genentech/Roche, Janssen, and Merck.

Thomas J. Herzog, MD, has disclosed that he has served as a scientific advisor to Clovis, Johnson & Johnson, and Tesaro.

Ursula Matulonis, MD, has disclosed that she has received consulting fees from ImmunoGen, Merck, and Mersana Therapeutics.

Bradley J. Monk, MD, FACS, FACOG, has disclosed that he has received consulting fees from AbbVie, Advaxis, Agenus, Amgen, AstraZeneca, ChemoCare, ChemoID, Clovis, Conjupro, Eisai, Geistlich, Genmab, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon (formally Oxigene), Merck, Myriad, Nucana, OncoMed, OncoQuest, OncoSec, Perthera, Pfizer, Precision Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, and VBL and fees for non-CME/CE services from AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, and Tesaro.

Kathleen Moore, MD, has disclosed that she has served on advisory boards for Aravive, AstraZeneca, Clovis, Cue Pharma, Genentech/Roche, Merck, Pfizer, OncoMed, Samumed, Tesaro, and VBL Therapeutics.

© 2020 Clinical Care Options, LLC. All rights reserved.

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate patients on potential treatments for stage II-IV epithelial ovarian cancer where systemic therapy is indicated. The information provided is based on the expert guidance of Robert L. Coleman, MD; Thomas J. Herzog, MD; Ursula Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; and Kathleen Moore, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the US Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Program Content